EZH2 and Parkinson disease: Similarly, another research by Sardoiwala et al. demonstrated the use of metformin‐loaded bio‐compatible polydopamine nanoformulation for treating PD by upregulating EZH2 mediated ubiquitination and proteasomal degradation of aggregated pSer129 α‐Syn pathway.192